|
|
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) |
|
Price: $90.7800
$7.57 
9.104%
|
| Day's High:
| $91.52999877929688
| Week Perf:
| 22.28 %
|
| Day's Low: |
$ 81.07 |
30 Day Perf: |
38.96 % |
| Volume (M): |
1,595,529 |
52 Wk High: |
$ 91.53 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$67.89 |
| Open: |
$82.71 |
52 Wk Low: |
$48.20 |
|
|
| Market Capitalization (Millions $) |
3,900 |
| Shares
Outstanding (Millions) |
43 |
| Employees |
370 |
| Revenues (TTM) (Millions $) |
535 |
| Net Income (TTM) (Millions $) |
-48 |
| Cash Flow (TTM) (Millions $) |
-74 |
| Capital Exp. (TTM) (Millions $) |
16 |
Business Description
Tarsus Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing and commercializing innovative therapies for ophthalmic diseases. The company aims to address unmet needs in the field of eye health by focusing on ocular surface and anterior segment conditions. Tarsus Pharmaceuticals is known for its expertise in the development of novel, small molecule therapeutics that target specific pathways involved in these diseases. The company's goal is to provide effective and safe treatment options to improve the lives of patients suffering from various eye disorders.
Company Address: 17700 Laguna Canyon Road Irvine 92618 CA
Company Phone Number: 418-1801 Stock Exchange / Ticker: NASDAQ TARS
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Shares
Published Wed, Mar 12 2025 8:13 PM UTC
IRVINE, Calif. In a significant development for investors and stakeholders alike, Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has announced the commencement of an underwritten public offering, initially aimed at raising $100 million through the sale of its common stock. As of March 13, 2025, the company has upsized this offering to $125 million, a clear reflection of robus...
|
| Shares
Published Thu, Mar 13 2025 1:50 AM UTC
Tarsus Pharmaceuticals Upsizes Public Offering to $125 Million Amid Strong Market ResponseIRVINE, Calif. March 12, 2025 Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a biopharmaceutical company focusing on innovative eye care solutions, has announced the pricing of an upsized underwritten public offering of approximately $125.0 million. This decision comes as Tarsus seeks t...
|
| Product Service News
Published Mon, Jan 13 2025 1:56 PM UTC
In an ambitious update, Tarsus Pharmaceuticals delineated its strategic progress toward establishing ocular rosacea as a pivotal therapeutic opportunity within the eye care sector, targeting launch dates as early as 2025. The definitive plan includes advancing their novel treatment candidate, TP-04 (lotilaner ophthalmic gel), through the initiation of a Phase 2 clinical stud...
|
| Product Service News
Published Tue, Apr 23 2024 12:30 PM UTC
Tarsus Pharmaceuticals Secures $200 Million Financing Commitment from Pharmakon, Bolstering Financial PositionIRVINE, Calif., April 23, 2024 - Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a company dedicated to addressing unmet medical needs and leveraging innovative science and technology to revolutionize patient care, has announced today its successful acquisition of $200 ...
|
| Shares
Published Fri, Mar 1 2024 5:08 AM UTC
Tarsus Pharmaceuticals Announces Pricing of $100 Million Public Offering
In a press release on March 1, 2024, Tarsus Pharmaceuticals, Inc. revealed the pricing of its underwritten public offering of 2,812,500 shares of common stock at $32.00 per share, as well as pre-funded warrants for an additional 312,500 shares at $31.9999. The company also granted the underwriters a...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-1.13 $ |
| Revenues (TTM) |
12.46 $
|
| Cash Flow (TTM) |
- |
| Cash |
6.67 $
|
| Book Value |
8.12 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
1,446,159 |
| Net
Income per Employee (TTM) |
-130,446 |
| Receivable Turnover Ratio (TTM) |
6.77 |
| Inventory Turnover Ratio (TTM) |
7.6 |
| Asset Turnover Ratio (TTM) |
0.99 |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.13 $
|
| Revenues (TTM) |
12.46 $ |
| Cash Flow (TTM) |
- |
| Cash |
6.67 $
|
| Book Value |
8.12 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Reportable Segment |
|
 100 % |
of total Revenue |
| Product sales net |
|
89.72 % |
of total Revenue |
| Product sales net Reportable Segment |
|
89.72 % |
of total Revenue |
| License fees and collaboration revenue |
|
10.28 % |
of total Revenue |
| License fees and collaboration revenue Reportable Segment |
|
10.28 % |
of total Revenue |
|
|
14.1%